ESMO 2023: Expert Perspectives & Insights into the Testing and Treatment of Melanoma - Episode 7
Key opinion leaders explain that clinicians should warn patients with BRAF-mutated metastatic melanoma starting BRAF/MEK inhibitor therapy about short-term toxicities like fever, chills, and rash that can differ greatly from immunotherapy toxicities.